466 related articles for article (PubMed ID: 33670427)
1. miR-582-5p Is a Tumor Suppressor microRNA Targeting the Hippo-YAP/TAZ Signaling Pathway in Non-Small Cell Lung Cancer.
Zhu B; V M; Finch-Edmondson M; Lee Y; Wan Y; Sudol M; DasGupta R
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33670427
[TBL] [Abstract][Full Text] [Related]
2. A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ.
Tan G; Cao X; Dai Q; Zhang B; Huang J; Xiong S; Zhang Yy; Chen W; Yang J; Li H
Oncotarget; 2015 Apr; 6(11):8676-86. PubMed ID: 25895125
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Hippo Signaling Pathway for Tissue Regeneration and Cancer Therapy.
Juan WC; Hong W
Genes (Basel); 2016 Aug; 7(9):. PubMed ID: 27589805
[TBL] [Abstract][Full Text] [Related]
4. YAP/TAZ and EZH2 synergize to impair tumor suppressor activity of TGFBR2 in non-small cell lung cancer.
Lo Sardo F; Pulito C; Sacconi A; Korita E; Sudol M; Strano S; Blandino G
Cancer Lett; 2021 Mar; 500():51-63. PubMed ID: 33296708
[TBL] [Abstract][Full Text] [Related]
5. LncRNA SFTA1P mediates positive feedback regulation of the Hippo-YAP/TAZ signaling pathway in non-small cell lung cancer.
Zhu B; Finch-Edmondson M; Leong KW; Zhang X; V M; Lin QXX; Lee Y; Ng WT; Guo H; Wan Y; Sudol M; DasGupta R
Cell Death Discov; 2021 Nov; 7(1):369. PubMed ID: 34845189
[TBL] [Abstract][Full Text] [Related]
6. Down-Regulated microRNA-192-5p Protects Against Hypoxic-Ischemic Brain Damage via Regulation of YAP1-Mediated Hippo Signaling Pathway.
Yan G; Tao Z; Xing X; Zhou Z; Wang X; Li X; Li F
Neurochem Res; 2022 May; 47(5):1243-1254. PubMed ID: 35084661
[TBL] [Abstract][Full Text] [Related]
7. Regulation of ferroptosis in cancer cells by YAP/TAZ and Hippo pathways: The therapeutic implications.
Sun T; Chi JT
Genes Dis; 2021 May; 8(3):241-249. PubMed ID: 33997171
[TBL] [Abstract][Full Text] [Related]
8. Suppression of microRNA-125a-5p upregulates the TAZ-EGFR signaling pathway and promotes retinoblastoma proliferation.
Zhang Y; Xue C; Zhu X; Zhu X; Xian H; Huang Z
Cell Signal; 2016 Aug; 28(8):850-60. PubMed ID: 27094723
[TBL] [Abstract][Full Text] [Related]
9. Yes-associated protein (YAP) and transcriptional coactivator with a PDZ-binding motif (TAZ): a nexus between hypoxia and cancer.
Zhao C; Zeng C; Ye S; Dai X; He Q; Yang B; Zhu H
Acta Pharm Sin B; 2020 Jun; 10(6):947-960. PubMed ID: 32642404
[TBL] [Abstract][Full Text] [Related]
10. Quantitative Real-Time PCR to Measure YAP/TAZ Activity in Human Cells.
Cao X; Zhao B
Methods Mol Biol; 2019; 1893():137-152. PubMed ID: 30565132
[TBL] [Abstract][Full Text] [Related]
11. Biological Significance of YAP/TAZ in Pancreatic Ductal Adenocarcinoma.
Hayashi H; Uemura N; Zhao L; Matsumura K; Sato H; Shiraishi Y; Baba H
Front Oncol; 2021; 11():700315. PubMed ID: 34395269
[TBL] [Abstract][Full Text] [Related]
12. MCM7 and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer.
Lo Sardo F; Forcato M; Sacconi A; Capaci V; Zanconato F; Di Agostino S; Del Sal G; Pandolfi PP; Strano S; Bicciato S; Blandino G
Carcinogenesis; 2017 Jan; 38(1):64-75. PubMed ID: 27797825
[TBL] [Abstract][Full Text] [Related]
13. MicroRNAs Regulating Hippo-YAP Signaling in Liver Cancer.
Lee NH; Kim SJ; Hyun J
Biomedicines; 2021 Mar; 9(4):. PubMed ID: 33808155
[TBL] [Abstract][Full Text] [Related]
14. MiR-33a Controls hMSCS Osteoblast Commitment Modulating the Yap/Taz Expression Through EGFR Signaling Regulation.
Costa V; Carina V; Raimondi L; De Luca A; Bellavia D; Conigliaro A; Salamanna F; Alessandro R; Fini M; Giavaresi G
Cells; 2019 Nov; 8(12):. PubMed ID: 31771093
[TBL] [Abstract][Full Text] [Related]
15. The Hippo Signaling Core Components YAP and TAZ as New Prognostic Factors in Lung Cancer.
Jiang Y; Xie WJ; Chen RW; You WW; Ye WL; Chen H; Chen WX; Xu JP
Front Surg; 2022; 9():813123. PubMed ID: 35388363
[TBL] [Abstract][Full Text] [Related]
16. SKI activates the Hippo pathway via LIMD1 to inhibit cardiac fibroblast activation.
Landry NM; Rattan SG; Filomeno KL; Meier TW; Meier SC; Foran SJ; Meier CF; Koleini N; Fandrich RR; Kardami E; Duhamel TA; Dixon IMC
Basic Res Cardiol; 2021 Apr; 116(1):25. PubMed ID: 33847835
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Hippo Signaling Improves Skin Lesions in a Rosacea-Like Mouse Model.
Lee J; Jung Y; Jeong SW; Jeong GH; Moon GT; Kim M
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33477764
[TBL] [Abstract][Full Text] [Related]
18. Cysteine S-Glutathionylation Promotes Stability and Activation of the Hippo Downstream Effector Transcriptional Co-activator with PDZ-binding Motif (TAZ).
Gandhirajan RK; Jain M; Walla B; Johnsen M; Bartram MP; Huynh Anh M; Rinschen MM; Benzing T; Schermer B
J Biol Chem; 2016 May; 291(22):11596-607. PubMed ID: 27048650
[TBL] [Abstract][Full Text] [Related]
19. miR-9-3p plays a tumour-suppressor role by targeting TAZ (WWTR1) in hepatocellular carcinoma cells.
Higashi T; Hayashi H; Ishimoto T; Takeyama H; Kaida T; Arima K; Taki K; Sakamoto K; Kuroki H; Okabe H; Nitta H; Hashimoto D; Chikamoto A; Beppu T; Baba H
Br J Cancer; 2015 Jul; 113(2):252-8. PubMed ID: 26125451
[TBL] [Abstract][Full Text] [Related]
20. YAP and TAZ Negatively Regulate Prox1 During Developmental and Pathologic Lymphangiogenesis.
Cho H; Kim J; Ahn JH; Hong YK; Mäkinen T; Lim DS; Koh GY
Circ Res; 2019 Jan; 124(2):225-242. PubMed ID: 30582452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
